General Information of This Payload
Payload ID
PAY0HXYLH
Name
F554443
Synonyms
F554443
   Click to Show/Hide
Target(s) Microtubule (MT)
Structure
Formula
C48H76N6O8
Isosmiles
CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(Cc1ccccc1)C(=O)O)OC)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)CCc1ccc(NC)cc1)C(C)C
InChI
InChI=1S/C48H76N6O8/c1-13-32(6)43(53(10)47(58)41(30(2)3)51-46(57)42(31(4)5)52(9)27-25-34-21-23-36(49-8)24-22-34)39(61-11)29-40(55)54-26-17-20-38(54)44(62-12)33(7)45(56)50-37(48(59)60)28-35-18-15-14-16-19-35/h14-16,18-19,21-24,30-33,37-39,41-44,49H,13,17,20,25-29H2,1-12H3,(H,50,56)(H,51,57)(H,59,60)
InChIKey
PYQZMUCAWOGBMY-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
865.17
Polar area
169.85
Complexity
62
xlogp Value
5.1004
Heavy Count
62
Rot Bonds
25
Hbond acc
9
Hbond Donor
4
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Lonigutamab ugodotin [Phase 2]
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT03316638  Phase Status Phase 1/2
Clinical Description
Phase 1/2 open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.
Revealed Based on the Cell Line Data
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% Low IGF1 expression (IGF1+)
Method Description
For the lung cancer models, 7-week-old female athymic nude mice (Envigo) were engrafted subcutaneously with 7 x106 SBC5 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
In Vitro Model Lung small cell carcinoma SBC-5 cells CVCL_1679
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 80.00% Moderate IGF1 expression (IGF1++)
Method Description
For the lung cancer models, 7-week-old female athymic nude mice (Envigo) were engrafted subcutaneously with 7 x106 NCI-H2122 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
In Vitro Model Lung adenocarcinoma NCI-H2122 cells CVCL_1531
Experiment 3 Reporting the Activity Date of This ADC [2]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% High IGF1 expression (IGF1+++)
Method Description
For the breast cancer model, 7-week-old female Swiss nude mice (Charles River Laboratories) were engrafted subcutaneously with 5 x106 MCF-7 cells 1 day after subcutaneous implantation of 0.72 mg 17-estradiol 60-day releasing pellets (Innovative Research of America) and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC [2]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% Moderate IGF1 expression (IGF1++)
Method Description
For the ovarian cancer model, 7-week-old female SCID mice (Charles River Laboratories) were engrafted subcutaneously with 10 x106 CaoV3 cells and treated with W0101 or isotype control ADC at 3 mg/kg every 4 days for 4 cycles.
In Vitro Model Lung adenocarcinoma NCI-H2122 cells CVCL_1531
Experiment 5 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.01 nM
High IGF1 expression (IGF1+++)
Method Description
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 6 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.63 nM
Moderate IGF1 expression (IGF1++)
Method Description
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.

   Click to Show/Hide
In Vitro Model Lung adenocarcinoma NCI-H2122 cells CVCL_1531
Experiment 7 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 nM Moderate IGF1 expression (IGF1++)
Method Description
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.

   Click to Show/Hide
In Vitro Model Ovarian serous adenocarcinoma Caov-3 cells CVCL_0201
Experiment 8 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 100.00 nM Low IGF1 expression (IGF1+)
Method Description
Tumor and normal cells were plated in 96-well flat bottomed microplates (100 L/well) in cell culture medium and incubated overnight at 37°C in 5% CO2. The next day, increasing concentrations of W0101 or isotype control ADC (010 ug/mL) were added into 3 replicate wells containing cells (10 L/well). Plates were incubated for 6 days at 37°C in 5% CO2. Cell viability was determined by measuring ATP using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). Luminescence was read using a Multimode Microplate Reader (Mithras LB940, Berthold Technologies). The percentage cell viability was calculated for each concentration considering 0 ug/mL ADC as 100% viability. The IC50 was calculated using Prism software. Three independent experiments were performed.

   Click to Show/Hide
In Vitro Model Lung small cell carcinoma SBC-5 cells CVCL_1679
References
Ref 1 Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study, NCT03316638
Ref 2 Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. Mol Cancer Ther. 2020 Jan;19(1):168-177.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.